Injectable formulations for organ augmentation

• US 9,724,367 B2
• Filed: 11/10/2011
• Issued: 08/08/2017
• Est. Priority Date: 11/10/2010
• Status: Active Grant

• Current Assignee: ProKidney LLC
• Original Assignee: RegenMed (Cayman) Ltd. (ProKidney Corp.)
• Inventors: Halberstadt, Craig R., Serban, Monica A., Basu, Joydeep, Payne, Richard, Robbins, Neil F., Jain, Deepak, Knight, Oluwatoyin A.
• Primary Examiner(s): Babic, Christopher M
• Assistant Examiner(s): Aron, Kimberly A
• Application Number:
  US13/883,433
• Publication Number:
  US 20130330364A1
• Time in Patent Office: 2,098 Days
• Field of Search: None
• CPC Class Codes: A61K 35/22 Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61L 2400/06 Flowable or injectable implant compositions
• CPC Class Codes: A61L 2430/26 for kidney reconstruction
• CPC Class Codes: A61L 27/222 Gelatin
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61P 13/12 of the kidneys

Abstract

The present invention concerns phase changing injectable formulations for organ augmentation containing active agents, such as bioactive cell populations, and methods of making and using the same.

Claims

1. An injectable formulation comprising bioactive cells and a temperature-sensitive cell-stabilizing biomaterial, wherein the cell-stabilizing biomaterial

consists of a hydrogel having a solid-to-liquid transitional state between 8°

C. and ambient temperature or above, and

wherein the bioactive cells are suspended in and are substantially uniformly dispersed throughout the volume of the cell-stabilizing biomaterial throughout the solid-to-liquid transitional state.

2. The formulation of claim 1, wherein the bioactive cells comprise renal cells.

3. The formulation of claim 1, wherein the hydrogel comprises gelatin.

4. The formulation of claim 3, wherein the gelatin is present in the formulation at about 0.5% to about 1% (w/v).

5. The formulation of claim 3, wherein the gelatin is present in the formulation at about 0.75% (w/v).

6. The formulation of claim 1, further comprising a cell viability agent.

7. The formulation of claim 6, wherein the cell viability agent comprises an agent selected from the group consisting of an antioxidant, an oxygen carrier, an immunomodulatory factor, a cell recruitment factor, a cell attachment factor, an anti-inflammatory agent, an immunosuppressant, an angiogenic factor, and a wound healing factor.

8. The formulation of claim 6, wherein the cell viability agent is an antioxidant.

9. The formulation of claim 8, wherein the antioxidant is 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid.

10. The formulation of claim 9, wherein the 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid is present at about 50 μ

M to about 150 μ

M.

11. The formulation of claim 9, wherein the 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid is present at about 100 μ

M.

12. The formulation of claim 7, wherein the cell viability agent is an oxygen carrier.

13. The formulation of claim 12, wherein the oxygen carrier is a perfluorocarbon.

14. The formulation of claim 7, wherein the cell viability agent is an immunomodulatory agent.

15. The formulation of claim 7, wherein the cell viability agent is an immunosuppressant.

24. The formulation of claim 1, further comprising biocompatible beads.

25. The formulation of claim 24, wherein the biocompatible beads are internally crosslinked.

26. The formulation of claim 25, wherein the crosslinked biocompatible beads have a reduced susceptibility to enzymatic degradation as compared to non-crosslinked biocompatible beads.

27. The formulation of claim 25, wherein the crosslinked biocompatible beads are carbodiimide-crosslinked beads.

28. The formulation of claim 27, wherein the carbodiimide is selected from the group consisting of 1-Ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (EDC), DCC—

N,N′

-dicyclohexylcarbodiimide (DCC), and N,N′

-Diisopropylcarbodiimide (DIPC).

29. The formulation of claim 27, wherein the carbodiimide is 1-Ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (EDC).

30. The formulation of claim 26, wherein the crosslinked biocompatible beads comprise a reduced number of free primary amines as compared to non-crosslinked biocompatible beads.

31. The formulation of claim 25, wherein the biocompatible beads are seeded with the bioactive cells.

32. The formulation of claim 31, wherein the bioactive cells are renal cells.

33. The formulation of claim 25, further comprising additional biocompatible beads that comprise a temperature-sensitive biomaterial, wherein the temperature-sensitive biomaterial consists of a hydrogel that maintains

(i) a substantially solid state at ambient temperature or below, and

(ii) a substantially liquid state at about 37°

C. or above.

34. The formulation of claim 33, wherein the temperature-sensitive biomaterial of the additional biocompatible beads comprises a solid-to-liquid transitional state between ambient temperature and about 37°

C.

35. The formulation of claim 33, wherein the substantially solid state is a gel state.

36. The formulation of claim 33, wherein the hydrogel comprises gelatin.

37. The formulation of claim 36, wherein the additional biocompatible beads comprise gelatin at about 5% (w/v) to about 10% (w/v).

38. The formulation of claim 33, wherein the additional biocompatible beads are spacer beads.

39. The formulation of claim 38, wherein the spacer beads are not seeded with bioactive cells.

40. The formulation of claim 2, further comprising products secreted by a renal cell population.

41. The formulation of claim 40, wherein the products comprise paracrine factors.

42. The formulation of claim 40, wherein the products comprise endocrine factors.

43. The formulation of claim 40, wherein the products comprise juxtacrine factors.

44. The formulation of claim 40, wherein the products comprise vesicles.

45. The formulation of claim 44, wherein the vesicles comprise microvesicles.

46. The formulation of claim 44, wherein the vesicles comprise exosomes.

47. The formulation of claim 44, wherein the vesicles comprise a secreted product selected from the group consisting of paracrine factors, endocrine factors, juxtacrine factors, and RNA.

16. An injectable formulation comprising bioactive renal cells, and a temperature-sensitive cell-stabilizing biomaterial, wherein the cell-stabilizing biomaterial consists of about 0.75% (w/v) gelatin and about 100 μ

M 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid, and wherein the cell-stabilizing biomaterial has

(i) a substantially solid state at about 8°

C. and below, and

(ii) a substantially liquid state at about ambient temperature and above,

wherein the biomaterial has a solid-to-liquid transitional state between 8°

C. and ambient temperature or above, and

wherein the bioactive renal cells are suspended in and substantially uniformly dispersed throughout the volume of the cell-stabilizing biomaterial throughout the transitional state.

17. The formulation of claim 16, wherein the substantially solid state is a gel state.

18. The formulation of claim 16, further comprising a cell viability agent.

19. The formulation of claim 18, wherein the cell viability agent comprises an agent selected from the group consisting of an antioxidant, an oxygen carrier, an immunomodulatory factor, a cell recruitment factor, a cell attachment factor, an anti-inflammatory agent, an angiogenic factor, and a wound healing factor.

20. The formulation of claim 19, wherein the cell viability agent is an oxygen carrier.

21. The formulation of claim 20, wherein the oxygen carrier is a perfluorocarbon.

22. The formulation of claim 19, wherein the cell viability agent is an immunomodulatory agent.

23. The formulation of claim 19, wherein the cell viability agent is an immunosuppressant.